Data Presented at ATTD 2017 Demonstrate Clinical Advantages of Tandem Diabetes Care Sensor-augmented Pump (SAP) over Medtronic MiniMed SAPs
- Additional Presentation of Self-reported Data Demonstrates Reduced Risk of Hypoglycemia with Tandem Pumps Compared to Previous Therapy -
"This study suggests that our simple-to-use touchscreen interface may
translate to improved clinical outcomes for people with diabetes," said
A retrospective study was conducted in which de-identified Tandem SAP
user data from the period of
- Reduced Hypoglycemia - Tandem SAP users showed reduced time in each of the hypoglycemic ranges. The effect size is large and persists regardless of the frequency of sensor usage.
- Increased Time in Range - Tandem SAP users who utilized the sensor at least 25% of the time showed increased time in range relative to Medtronic SAP users with the same sensor usage time.
- Improved Overall Glycemic Control - The Tandem SAP demonstrated improved control across all glycemic ranges for subjects using the sensor at least 75% of the time. These users spent less time both hypoglycemic and hyperglycemic when compared to users of the Medtronic SAPs.
Based on earlier data demonstrating a greater ease-of-use and lower rate of error for the t:slim® Insulin Pump2, the current results may be related to the usability benefits introduced by the touchscreen, suggesting that the intuitive user interface of the Tandem SAP translates into better outcomes in everyday life.
In a second poster presentation, data were presented from a study demonstrating a reduced risk of hypoglycemia associated with Tandem pump use compared to previous methods of diabetes therapy. Data were collected from patients with either type 1 (90%) or type 2 (10%) diabetes who had been using a Tandem pump for at least 1 year (N = 1,370). Participants voluntarily filled out an online survey with questions about the occurrence of mild hypoglycemic events (able to treat the low themselves), medium hypoglycemic events (needed assistance from someone but did not need to go to the hospital) and severe hypoglycemic events (needed assistance from a medical professional and/or needed to go the hospital). Questions focused on both the year before starting a Tandem pump (using previous method of diabetes therapy) and the past year using their Tandem pump. Results demonstrated that, even when controlling for CGM usage, Tandem pump users reported a 52% reduction in severe hypoglycemia, a 31% reduction in medium hypoglycemia, and a 15% reduction in mild hypoglycemia, compared to previous methods of diabetes therapy. Furthermore, there was a statistically significant reduction in ambulance rides due to severe hypoglycemia of 58% and in days spent at the hospital due to severe hypoglycemia of 50%.
Any forward-looking statements are subject to risks and uncertainties
including those identified in the Company's most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, as well as other documents
that the Company files with the
t:slim, t:flex and
1 Battelino T, Liabat S, Veeze HJ, Castañeda J, Arrieta A,
Cohen O. Routine use of continuous glucose monitoring in 10 501 people
with diabetes mellitus. Diabet Med. 2015;32:1568-1574.
News Provided by Acquire Media